Developer docs
API playgroundTry for free, no card

Search company profiles

Qualitis

Full company profile

uuid000pgbn

Namestring
Qualitis
Legal namestring
Optimapharm d.o.o.
Websiteurl
qualitis.gr
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Qualitis is positioned in the source data as a privately held clinical development and research services provider, with the underlying operational entity identified as Optimapharm d.o.o., a Croatian limited liability company. Note: the firmographic header lists Qualitis in Athens, Greece (website qualitis.gr, founded 2006, 51-100 employees), while the bulk of the operational data describes Optimapharm d.o.o. headquartered in Zagreb, Croatia; this discrepancy is preserved as observed rather than reconciled.

The company operates as a Contract Research Organization (CRO) delivering three core services: Full Service Phase I-IV clinical trial management, Functional Service Provision (FSP) for targeted clinical operations support, and Real World Research for observational studies and real-world evidence generation. Underlying these services are five branded therapeutic platforms — OptimaCardio (cardiology), OptimaImmuno (immunology), OptimaDerm (dermatology), OptimaOnco (oncology), and OptimaNeuro (neurology) — which the firm markets as "integrated therapeutic platforms" designed to deliver broader patient access and regulatory advantage. No proprietary software, APIs, or AI/ML systems are disclosed in the source.

The business model is enterprise professional services: custom, project-based contracts with pharmaceutical, biotechnology, and medical device sponsors, sold directly through a Request Proposal process and supported by a field sales team. Pricing is not publicly disclosed, and engagements are structured as multi-year contracts. The company maintains offices in Zagreb (global headquarters), Boston (US head office), and Chennai, India (APAC head office), and self-reports 2x the geographic reach across North America and Europe compared to the average mid-sized CRO. The company is privately held with no disclosed funding rounds, parent company, or institutional investors. No customer logos, named sponsors, patents, certifications, or M&A activity are present in the source data.

Short descriptiontext

Qualitis operates as a privately held Contract Research Organization (CRO) providing Phase I-IV clinical trial management, functional service provision, and real-world research services to pharmaceutical, biotechnology, and medical device sponsors across five therapeutic areas, with offices in Zagreb, Boston, and Chennai.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, contract research organization, clinical trial management, functional service provision, real world evidence
Industry2 codes
PRIMARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (CRO) Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Full-service Phase I-IV clinical trial management and Functional Service Provision (FSP) for pharmaceutical and biotech sponsors. Revenue generated through project-based contracts for clinical development programs.

optimapharmgroup.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

optimapharmgroup.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1OptimaCardio Suite
Description

Cardiology therapeutic platform

optimapharmgroup.com
+4 more records
Core offering1 text field

Qualitis (operating as Optimapharm) is a Contract Research Organization providing full-service Phase I-IV clinical trial management, Functional Service Provision (FSP), and Real World Research to pharmaceutical, biotechnology, and medical device sponsors. Services are delivered through five integrated therapeutic platforms covering cardiology, immunology, dermatitis, oncology, and neurology, with global operations spanning Croatia, the United States, and India.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 2x more reach across North America and Europe than the average mid-sized CRO
Product overview1 text field

Optimapharm is a Contract Research Organization (CRO) providing integrated clinical research services. The company operates a unified service model consisting of three core offerings: Full Service Phase I-IV (comprehensive end-to-end clinical trial management), Functional Service Provision (FSP - flexible, targeted support services), and Real World Research (observational studies and real-world evidence generation). The company maintains therapeutic expertise platforms across five key areas: Cardiology (OptimaCardioSuite), Immunology (OptimaImmunoSuite), Dermatology (OptimaDermSuite), Oncology (OptimaOncoSuite), and Neurology (OptimaNeuroSuite). Optimapharm emphasizes its global reach across North America, Europe, and APAC, with operations spanning Croatia (headquarters), Boston, USA, and Chennai, India.

Product and service3 records
1Full Service Phase I-IV
2Functional Service Provision (FSP)
CategoryClinical trial services
Description

Flexible functional service provision offering targeted clinical trial support such as monitoring, data management, and regulatory affairs on a dedicated or distributed basis for sponsors that need targeted resourcing rather than full-service outsourcing.

3Real World Research
CategoryReal-world evidence services
Description

Real-world evidence and observational research services that generate evidence from clinical practice settings to support regulatory submissions and market access for pharmaceutical and biotechnology sponsors.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global clinical and commercial solutions provider offering full-service clinical operations, FSP, and real-world evidence. Direct overlap with Optimapharm's three core services from a much larger commercial footprint.

TypeDirect peer
Description

CRO/CDMO with strong early-phase and discovery presence that has expanded into Phase II-IV clinical services. Comparable therapeutic-area emphasis (particularly CNS/oncology), giving it a similar sponsor-value proposition in biotech.

TypeBroad incumbent
Description

One of the largest global CROs following the PRA Health acquisition, offering full-service, FSP, and real-world evidence across all therapeutic areas. Represents the scaled incumbent Optimapharm competes against for full-service Phase III enterprise work.

TypeDirect peer
Description

Mid-to-large full-service CRO operating with a therapeutic-area specialization model that mirrors Optimapharm's branded OptimaCardio/OptimaOnco suites. Both compete for biotech and mid-sized pharma Phase II-IV work, making Medpace the most size- and model-comparable peer.

TypeDirect peer
Description

Global full-service and FSP CRO with broad therapeutic-area coverage and major presence in Europe and North America. Directly competes for Optimapharm's pharma and biotech sponsor RFPs across Phase I-IV and functional service contracts.

TypeEmerging player
Description

Smaller, therapeutically focused CRO offering adaptive trial designs and full-service capabilities to mid-sized biotech. Addresses a similar sponsor segment to Optimapharm with a narrower therapeutic footprint.

TypeDirect peer
Description

Mid-sized, therapeutically focused CRO emphasizing neuroscience, oncology, and immunology — overlapping heavily with Optimapharm's OptimaNeuro and OptimaOnco platforms. Comparable size, therapeutic emphasis, and sponsor mix make it a high-relevance peer.

TypeBroad incumbent
Description

Largest global CRO with proprietary technology platforms, real-world data assets, and preferred-vendor status with major pharma. Defines the upper bound of scale and capability that Optimapharm must differentiate against.

TypeEmerging player
Description

Mid-sized full-service CRO with a clinical operations and biostatistics emphasis similar to an FSP-led delivery model. Competes for the same therapeutic-area focused mid-size biotech programs.

TypeDirect peer
Description

European-headquartered mid-sized CRO with global delivery footprint and therapeutic-area specialization. Closest match in terms of size, geography, and operating model to Optimapharm.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qualitis

Contract Research Organization (CRO) Servicesqualitis.gr

Qualitis operates as a privately held Contract Research Organization (CRO) providing Phase I-IV clinical trial management, functional service provision, and real-world research services to pharmaceutical, biotechnology, and medical device sponsors across five therapeutic areas, with offices in Zagreb, Boston, and Chennai.

What Qualitis does

Qualitis is positioned in the source data as a privately held clinical development and research services provider, with the underlying operational entity identified as Optimapharm d.o.o., a Croatian limited liability company. Note: the firmographic header lists Qualitis in Athens, Greece (website qualitis.gr, founded 2006, 51-100 employees), while the bulk of the operational data describes Optimapharm d.o.o. headquartered in Zagreb, Croatia; this discrepancy is preserved as observed rather than reconciled.

The company operates as a Contract Research Organization (CRO) delivering three core services: Full Service Phase I-IV clinical trial management, Functional Service Provision (FSP) for targeted clinical operations support, and Real World Research for observational studies and real-world evidence generation. Underlying these services are five branded therapeutic platforms — OptimaCardio (cardiology), OptimaImmuno (immunology), OptimaDerm (dermatology), OptimaOnco (oncology), and OptimaNeuro (neurology) — which the firm markets as "integrated therapeutic platforms" designed to deliver broader patient access and regulatory advantage. No proprietary software, APIs, or AI/ML systems are disclosed in the source.

The business model is enterprise professional services: custom, project-based contracts with pharmaceutical, biotechnology, and medical device sponsors, sold directly through a Request Proposal process and supported by a field sales team. Pricing is not publicly disclosed, and engagements are structured as multi-year contracts. The company maintains offices in Zagreb (global headquarters), Boston (US head office), and Chennai, India (APAC head office), and self-reports 2x the geographic reach across North America and Europe compared to the average mid-sized CRO. The company is privately held with no disclosed funding rounds, parent company, or institutional investors. No customer logos, named sponsors, patents, certifications, or M&A activity are present in the source data.

Qualitis firmographics

Firmographics
Name
Qualitis
Legal name
Optimapharm d.o.o.
Website
https://qualitis.gr
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Qualitis operates as a privately held Contract Research Organization (CRO) providing Phase I-IV clinical trial management, functional service provision, and real-world research services to pharmaceutical, biotechnology, and medical device sponsors across five therapeutic areas, with offices in Zagreb, Boston, and Chennai.
Ownership category
akta.pro rank

Qualitis industry classification

Industry
Product category
Contract Research Organization (CRO) Services
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Clinical research services
  • Contract research organization
  • Clinical trial management
  • Functional service provision
  • Real world evidence

Where Qualitis is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices3 records

Markets served

Qualitis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: Full-service Phase I-IV clinical trial management and Functional Service Provision (FSP) for pharmaceutical and biotech sponsors. Revenue generated through project-based contracts for clinical development programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Qualitis product offering

Product offering

Core offering

Qualitis (operating as Optimapharm) is a Contract Research Organization providing full-service Phase I-IV clinical trial management, Functional Service Provision (FSP), and Real World Research to pharmaceutical, biotechnology, and medical device sponsors. Services are delivered through five integrated therapeutic platforms covering cardiology, immunology, dermatitis, oncology, and neurology, with global operations spanning Croatia, the United States, and India.

Product overview

Optimapharm is a Contract Research Organization (CRO) providing integrated clinical research services. The company operates a unified service model consisting of three core offerings: Full Service Phase I-IV (comprehensive end-to-end clinical trial management), Functional Service Provision (FSP - flexible, targeted support services), and Real World Research (observational studies and real-world evidence generation). The company maintains therapeutic expertise platforms across five key areas: Cardiology (OptimaCardioSuite), Immunology (OptimaImmunoSuite), Dermatology (OptimaDermSuite), Oncology (OptimaOncoSuite), and Neurology (OptimaNeuroSuite). Optimapharm emphasizes its global reach across North America, Europe, and APAC, with operations spanning Croatia (headquarters), Boston, USA, and Chennai, India.

Differentiator

Problem solved

Functional benefit

Brands

  • OptimaCardio Suite: Cardiology therapeutic platform
  • OptimaImmuno Suite
  • OptimaDerm Suite
  • OptimaOnco Suite
  • OptimaNeuro Suite

Products and services

  • Full Service Phase I-IV
  • Functional Service Provision (FSP) Flexible functional service provision offering targeted clinical trial support such as monitoring, data management, and regulatory affairs on a dedicated or distributed basis for sponsors that need targeted resourcing rather than full-service outsourcing.
  • Real World Research Real-world evidence and observational research services that generate evidence from clinical practice settings to support regulatory submissions and market access for pharmaceutical and biotechnology sponsors.

Quantifiable outcome

  • 2x more reach across North America and Europe than the average mid-sized CRO

Companies that use Qualitis

Customer profile

Segments3 records

Ideal customer profiles3 records

Qualitis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Qualitis partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Qualitis competitors and assessment

Company assessment

Broad incumbents

  • Syneos Health: Global clinical and commercial solutions provider offering full-service clinical operations, FSP, and real-world evidence. Direct overlap with Optimapharm's three core services from a much larger commercial footprint.
  • ICON plc: One of the largest global CROs following the PRA Health acquisition, offering full-service, FSP, and real-world evidence across all therapeutic areas. Represents the scaled incumbent Optimapharm competes against for full-service Phase III enterprise work.
  • IQVIA: Largest global CRO with proprietary technology platforms, real-world data assets, and preferred-vendor status with major pharma. Defines the upper bound of scale and capability that Optimapharm must differentiate against.

Direct peers

  • Charles River Laboratories: CRO/CDMO with strong early-phase and discovery presence that has expanded into Phase II-IV clinical services. Comparable therapeutic-area emphasis (particularly CNS/oncology), giving it a similar sponsor-value proposition in biotech.
  • Medpace Holdings: Mid-to-large full-service CRO operating with a therapeutic-area specialization model that mirrors Optimapharm's branded OptimaCardio/OptimaOnco suites. Both compete for biotech and mid-sized pharma Phase II-IV work, making Medpace the most size- and model-comparable peer.
  • Parexel International: Global full-service and FSP CRO with broad therapeutic-area coverage and major presence in Europe and North America. Directly competes for Optimapharm's pharma and biotech sponsor RFPs across Phase I-IV and functional service contracts.
  • Worldwide Clinical Trials: Mid-sized, therapeutically focused CRO emphasizing neuroscience, oncology, and immunology — overlapping heavily with Optimapharm's OptimaNeuro and OptimaOnco platforms. Comparable size, therapeutic emphasis, and sponsor mix make it a high-relevance peer.
  • TFS HealthScience: European-headquartered mid-sized CRO with global delivery footprint and therapeutic-area specialization. Closest match in terms of size, geography, and operating model to Optimapharm.

Emerging players

  • Clinipace Worldwide: Smaller, therapeutically focused CRO offering adaptive trial designs and full-service capabilities to mid-sized biotech. Addresses a similar sponsor segment to Optimapharm with a narrower therapeutic footprint.
  • Rho (Contract Research Organization): Mid-sized full-service CRO with a clinical operations and biostatistics emphasis similar to an FSP-led delivery model. Competes for the same therapeutic-area focused mid-size biotech programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Qualitis social profiles

Digital presence

Qualitis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qualitis leadership team

Management profile

Number of profiles

Qualitis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qualitis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qualitis

What does Qualitis do?

Qualitis (operating as Optimapharm) is a Contract Research Organization providing full-service Phase I-IV clinical trial management, Functional Service Provision (FSP), and Real World Research to pharmaceutical, biotechnology, and medical device sponsors. Services are delivered through five integrated therapeutic platforms covering cardiology, immunology, dermatitis, oncology, and neurology, with global operations spanning Croatia, the United States, and India.

Is Qualitis a public or private company?

Qualitis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Qualitis founded?

Qualitis was founded in 2006. It employs 51 to 100 people.

Where is Qualitis based?

Qualitis is headquartered in Athens, Greece, in the Europe region.

How does Qualitis make money?

One revenue line is on record: clinical Research Services.

Who are Qualitis's main competitors?

Broad incumbents on record are Syneos Health, ICON plc and IQVIA. Direct peers are Charles River Laboratories, Medpace Holdings, Parexel International, Worldwide Clinical Trials and TFS HealthScience. Emerging players are Clinipace Worldwide and Rho (Contract Research Organization).

Does Qualitis have an API?

No public API is recorded for Qualitis.

What industry is Qualitis in?

Qualitis's product category is Contract Research Organization (CRO) Services. Its primary akta.pro industry code is HLAGAOAA, Clinical Operations & Monitoring FSP (CRA/CTM/Start-up), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 62151 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales